Literature DB >> 1624590

Pathogenesis of idiopathic myelofibrosis: role of growth factors.

J T Reilly1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1624590      PMCID： PMC495214          DOI： 10.1136/jcp.45.6.461

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  47 in total

1.  Autocrine and/or paracrine mechanism operate during the growth of human bone marrow fibroblasts.

Authors:  A Kimura; O Katoh; H Hyodo; S Kusumi; A Kuramoto
Journal:  Br J Haematol       Date:  1991-08       Impact factor: 6.998

2.  Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts.

Authors:  A Kimura; O Katoh; H Hyodo; A Kuramoto
Journal:  Br J Haematol       Date:  1989-08       Impact factor: 6.998

3.  Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.

Authors:  O Katoh; A Kimura; T Itoh; A Kuramoto
Journal:  Am J Hematol       Date:  1990-11       Impact factor: 10.047

4.  Synthesis of transforming growth factor-beta 1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-granules.

Authors:  R A Fava; T T Casey; J Wilcox; R W Pelton; H L Moses; L B Nanney
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

5.  Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.

Authors:  C Rozman; M Giralt; E Feliu; D Rubio; M T Cortés
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

Review 6.  Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.

Authors:  F Mertens; B Johansson; S Heim; U Kristoffersson; F Mitelman
Journal:  Leukemia       Date:  1991-03       Impact factor: 11.528

7.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.

Authors:  R J Jacobson; A Salo; P J Fialkow
Journal:  Blood       Date:  1978-02       Impact factor: 22.113

8.  The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study.

Authors:  A Carroll; C Civin; N Schneider; G Dahl; A Pappo; P Bowman; A Emami; S Gross; C Alvarado; C Phillips
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

9.  A reversible defect of platelet PDGF content in myeloproliferative disorders.

Authors:  T P Baglin; S M Price; B J Boughton
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

10.  Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)

Authors:  P Gimsing; O W Bjerrum; E Brandt; J Ellegaard; S A Evensen; M M Hansen; M Hedenus; E Hippe; N Keldsen; I Palva
Journal:  Br J Haematol       Date:  1991-01       Impact factor: 6.998
View more
  7 in total

1.  Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis.

Authors:  Judit Bedekovics; Attila Kiss; Lívia Beke; Katalin Károlyi; Gábor Méhes
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

2.  Small cell variant of Ki-1 lymphoma associated with myelofibrosis and a novel constitutional chromosomal translocation t(3;4) (q13;q12).

Authors:  W Yeo; N Wong; J Chow; W C Tsoi; P J Johnson; N Wickham
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

3.  Tenascin immunoreactivity in normal and pathological bone marrow.

Authors:  Y Soini; D Kamel; M Apaja-Sarkkinen; I Virtanen; V P Lehto
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

4.  TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.

Authors:  Medhat Shehata; Josef D Schwarzmeier; Martin Hilgarth; Rainer Hubmann; Markus Duechler; Heinz Gisslinger
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

5.  A new fibroblast growth stimulating activity from the human megakaryoblastic leukaemia cell line ELF-153: in vitro and in vivo findings.

Authors:  H T Hassan; A R Hanauske; E Lux; H D Kleine; M Freund
Journal:  Int J Exp Pathol       Date:  1995-10       Impact factor: 1.925

6.  Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Authors:  Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Journal:  Ther Clin Risk Manag       Date:  2012-03-01       Impact factor: 2.423

7.  Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis.

Authors:  Frederike Kramer; Jens Dernedde; Artur Mezheyeuski; Rudolf Tauber; Patrick Micke; Kai Kappert
Journal:  Haematologica       Date:  2019-10-31       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.